Xin Lang Cai Jing·2025-11-19 01:29Group 1 - The core viewpoint of the news is that Spring Medical experienced a decline in stock price and significant financing activity on November 18, with a net financing outflow of 750.12 million yuan [1] - On November 18, Spring Medical's financing buy-in amounted to 532.20 million yuan, while the financing repayment was 1,282.32 million yuan, resulting in a total financing balance of 5,483.15 million yuan, which represents 0.73% of the circulating market value [1] - The company's financing balance is at a high level, exceeding the 90th percentile of the past year [1] Group 2 - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, with a primary focus on joint prosthetics and spinal implants [2] - The company reported a revenue of 756 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, which is a 213.21% increase year-on-year [2] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2] Group 3 - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders as of September 30, 2025, Hong Kong Central Clearing Limited is the fourth largest new shareholder with 2.9585 million shares, while China Europe Economic Selection Mixed A and Ping An Low Carbon Economy Mixed A are also new entrants in the top five [3] - South Pharmaceutical Health Flexible Allocation Mixed A has exited the list of the top ten circulating shareholders [3]